Back to articles

Denosumab is a good option for patients receiving glucocorticoids


Use of denosumab (Prolia—Amgen) for 12 months was shown to be both noninferior and superior to risedronate on select bone mineral density endpoints for patients newly initiating glucocorticoids or those continuing therapy, according to results of a trial published in The Lancet Diabetes and Endocrinology.

Recent Articles